Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma

Oncology Reports

Volumn 23, Issue 5, 2010, Pages 1269-1276

  Jung, Tae Young ^a   Jung, Shin ^a   Moon, Kyung Sub ^a   Kim, In Young ^a   Kang, Sam Suk ^a   Kim, Young Hee ^a   Park, Chang Soo ^a   Lee, Kyung Hwa ^a  

^a Chonnam National University   (South Korea)

Author keywords

Chemotherapy; Glioblastoma; Immunohistochemistry; MGMT promoter methylation; MGMT protein; Re operation

Indexed keywords

CISPLATIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIMUSTINE; STEROID; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; MICROSURGERY; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REOPERATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROSURGERY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROSURGICAL PROCEDURES; NIMUSTINE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RADIOTHERAPY, ADJUVANT; REOPERATION; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 77950833837     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000760     Document Type: Article

References (29)

1. Ammirati M, Vick N, Liao YL, Ciric I and Mikhael M: Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 21: 201-206, 1987.
2. Harsh GR IV, Levin VA, Gutin PH, Seager M, Silver P and Wilson CB: Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21: 615-621, 1987.
3. Salcman M, Kaplan RS, Ducker TB, Adbo H and Montgomery E: Effect of age and reoperation on survival in the combined modality treatment of malignant astrocytoma. Neurosurgery 10: 454-463, 1982.
4. Harris LC, Remack JS and Brent TP: Identification of a 59 bp enhancer located at the first exon/intron boundary of the human O6-methylguanine DNA methyltransferase gene. Nucleic Acids Res 22: 4614-4619, 1994.
5. Bae SI, Lee HS, Kim SH and Kim WH: Inactivation of O6- methylguanine-DNA methyltransferase by promoter cpg island hypermethylation in gastric cancers. Br J Cancer 86: 1888-1892, 2002.
6. Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM, Belanich M, Yarosh DB, Bearman SI, Giroux DJ and Schold SC: Correlation of tumor O6-methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 16: 3310-3315, 1998.
7. Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, Garcia-Lopez JL, Piquer J, Safont MJ, Balana C, Sanchez-Cespedes M, Garcia-Villanueva M, Arribas L and Esteller M: CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 10: 4933-4938, 2004.
8. Brell M, Tortosa A, Verger E, Gil JM, Vinolas N, Villa S, Acebes JJ, Caral L, Pujol T, Ferrer I, Ribalta T and Graus F: Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11: 5167-5174, 2005.
9. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343: 1350-1354, 2000.
10. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018, 2002.
11. Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, Kang SS, Park CS, Lee KH and Chae HJ: The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Neurosurgery 65: 866-875, 2009.
12. Cavenee WK, Furnari FB and Nagane M: Astrocytic tumors. In: Pathology and Genetics. Tumours of the Nervous System. Kleihues P and Cavenee WK (eds). IARC Press 26, Lyon, pp27-29, 2000.
13. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
14. Scott CB, Scarantino C, Urtasun R, Movsas B, Jones CU, Simpson JR, Fischbach AJ and Curran WJ Jr: Validation and predictive power of radiation therapy oncology group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-60. Int J Radiat Oncol Biol Phys 40: 51-55, 1998.
15. Bredel M and Zentner J: Brain-tumor drug resistance: the bare essentials. Lancet Oncol 3: 397-406, 2002.
16. Pieper RO, Patel S, Ting SA, Futscher BW and Costello JF: Methylation of CpG island transcription factor binding sites is unnecessary for aberrant silencing of the human MGMT gene. J Biol Chem 271: 13916-13924, 1996.
17. Parkinson JF, Wheeler HR, Clarkson A, McKenzie CA, Biggs MT, Little NS, Cook RJ, Messina M, Robinson BG and McDonald KL: Variation of O6-methylguanine-DNA mehtyltransferase (MGMT) promoter mehtylation in serial samples in glioblastomas. J Neurooncol 87: 71-78, 2008.
18. Blanc JL, Wager M, Guilhot J, Kusy S, Bataille B, Chantereau T, Lapierre F, Larsen CJ and Karayan-Tapon L: Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas. J Neurooncol 68: 275-283, 2004.
19. Costello JF, Futscher BW, Tano K, Graunke DM and Pieper RO: Graded methylation in the promoter and in the body of the O6- methylguanine-DNA methyltransferase gene correlates with MGMT expression in human glioma cells. J Biol Chem 269: 17228-17237, 1996.
20. Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, Issa JP, Sidransky D, Baylin SB and Herman JG: Inactivation of the DNA repair gene O6- methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 60: 2368-2371, 2000.
21. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH and Modrich PL: DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16: 3851-3857, 1998.
22. Liu L, Allay E, Dumenco LL and Gerson SL: Rapid repair of O6-methylguanine-DNA adducts protects transgenic mice from N-methylnitrosourea- induced thymic lymphomas. Cancer Res 54: 4648-4652, 1994.
23. Margison GP, Povey AC, Kaina B and Santibanez Koref MF: Variability and regulation of O6-alkylguanine-DNA alkyltransferase. Carcinogenesis 24: 625-635, 2003.
24. Grasbon-Frodl EM, Kreth FW, Ruiter M, Schnell O, Bise K, Felsberg J, Reifenberger G, Tonn JC and Kretzschmar HA: Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 121: 2458-2464, 2007.
25. Preusser M, Charles Janzer R, Felsberg J, Reifenberger G, Hamou MF, Diserens AC, Stupp R, Gorlia T, Marosi C, Heinzl H, Hainfellner JA and Hegi M: Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18: 520-532, 2008.
26. Baylin SB and Herman JG: DNA hypermethylation in tumorigenesis: epigenetic joins genetics. Trends Genet 16: 168-173, 2000.
27. Bhakat KK and Mitra S: CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration. Carcinogenesis 24: 1337-1345, 2003.
28. Park TJ, Han SU, Choy K, Paik WK, Kim YB and Lim IK: Methylation of O6-methylguanine-DNA methyltransferase gene is associated significantly with k-ras mutation, lymph node invasion, tumor staging, and disease-free survival in patients with gastric carcinoma. Cancer 92: 2760-2768, 2001.
29. Rood BR, Zhang H and Cogen PH: Intercellular heterogeneity of expression of the MGMT DNA repair gene in pediatric medulloblastoma. Neuro Oncol 6: 200-207, 2004.